文献速递心脑血管急症创伤与烧伤

胶质纤维酸性蛋白与泛素C末端水解酶L1诊断急性创伤性颅内病变:PIONEER诊断准确性研究

Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase L1 for Acute Traumatic Intracranial Lesions: The PIONEER Diagnostic Accuracy Study.
PubMed 文献 · Ann Emerg Med · 2025-10-10
一句话结论成人钝性创伤后≤24小时联合检测血浆GFAP与UCH-L1,对临床显著急性创伤性颅内病变敏感度达96%,在无凝血病的拟实施队列中敏感度100%。

本研究为回顾性研究,纳入1867例≥18岁、因创伤相关主诉就诊、接受脑CT且伤后≤24小时留有残余血样的急诊患者,评估Abbott i-STAT TBI血浆检测GFAP与UCH-L1对临床显著急性创伤性颅内病变的诊断准确性。1867例中49例(2.6%)存在临床显著创伤性颅内病变。GFAP或UCH-L1升高者敏感度96%(95%CI 86%~99%)、特异度30%(95%CI 28%~32%)、阳性似然比1.38(95%CI 1.29~1.47)、阴性似然比0.13(95%CI 0.03~0.53);2例有临床显著CT病变但GFAP与UCH-L1未升高。在拟实施队列(≥18岁且无凝血病)中,GFAP或UCH-L1升高的敏感度100%(95%CI 86%~100%)、特异度33%(95%CI 31%~36%)、阳性似然比1.50(95%CI 1.44~1.56)、阴性似然比0.00(95%CI 0.00~0.95)。作者结论认为联合检测敏感度高,但尚需进一步研究确定在该拟实施队列中应用这些生物标志物能否减少可避免的脑CT检查。

要点

  • 1867例成人钝性创伤患者中49例(2.6%)存在临床显著急性创伤性颅内病变,GFAP或UCH-L1升高诊断敏感度96%(95%CI 86%~99%)、特异度30%(95%CI 28%~32%)。
  • GFAP或UCH-L1升高的阴性似然比为0.13(95%CI 0.03~0.53),但仍有2例临床显著CT病变患者GFAP与UCH-L1均未升高。
  • 在≥18岁且无凝血病的拟实施队列中,GFAP或UCH-L1升高诊断敏感度100%(95%CI 86%~100%)、特异度33%(95%CI 31%~36%)、阴性似然比0.00(95%CI 0.00~0.95)。
  • 生物标志物检测采用Abbott i-STAT TBI Plasma test,血样为伤后≤24小时采集的残余样本。
  • 作者结论认为联合检测敏感度高,但能否减少可避免的脑CT检查尚需进一步研究确定。

适用人群与场景

  • ≥18岁、因创伤相关主诉就诊于急诊科、接受脑CT检查、且伤后≤24小时留有残余血样的钝性创伤患者。
  • 拟实施队列为≥18岁且无凝血病的成人患者。

研究设计与关键结果

  • 研究类型为回顾性研究,纳入1867例≥18岁钝性创伤急诊患者,49例(2.6%)存在临床显著急性创伤性颅内病变。
  • GFAP或UCH-L1升高诊断临床显著急性创伤性颅内病变的敏感度96%(95%CI 86%~99%)、特异度30%(95%CI 28%~32%)、阳性似然比1.38(95%CI 1.29~1.47)、阴性似然比0.13(95%CI 0.03~0.53)。
  • 2例患者存在临床显著CT病变但GFAP与UCH-L1未升高。
  • 在≥18岁且无凝血病的拟实施队列中,GFAP或UCH-L1升高的敏感度100%(95%CI 86%~100%)、特异度33%(95%CI 31%~36%)、阳性似然比1.50(95%CI 1.44~1.56)、阴性似然比0.00(95%CI 0.00~0.95)。

证据类型、等级与局限

  • 证据类型:回顾性诊断准确性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,伤后≤24小时联合检测血浆GFAP与UCH-L1对临床显著急性创伤性颅内病变敏感度高;能否通过在该拟实施队列中应用这些生物标志物减少可避免的脑CT检查,尚需进一步研究确定。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

STUDY OBJECTIVE: To determine the diagnostic accuracy of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1) for detecting clinically significant acute traumatic intracranial lesions in emergency department patients who undergo brain computed tomography (CT) after blunt trauma.

METHODS: We conducted a retrospective study of 1,867 patients aged more than or equal to 18 years, who presented with trauma-related complaints, underwent brain CT, and had residual samples collected less than or equal to 24 hours postinjury. We evaluated the diagnostic accuracy of GFAP and UCH-L1 using the Abbott i-STAT TBI Plasma test. Additionally, we assessed diagnostic accuracy within key clinical subgroups to define a proposed implementation cohort and assessed the diagnostic accuracy of the biomarkers within this cohort.

RESULTS: Among 1,867 patients, 49 (2.6%) had clinically significant traumatic intracranial lesions. Elevated GFAP or UCH-L1 demonstrated 96% sensitivity (95% confidence interval [CI] 86% to 99%), 30% specificity (95% CI 28% to 32%), positive likelihood ratio (LR+) of 1.38 (95% CI 1.29 to 1.47), and negative likelihood ratio (LR-) of 0.13 (95% CI 0.03 to 0.53). Two patients had clinically significant CT lesions without elevated GFAP or UCH-L1. In the proposed implementation cohort of adults aged more than or equal to 18 years without coagulopathy elevated GFAP or UCH-L1 had a sensitivity of 100% (95% CI 86% to 100%), specificity of 33% (95% CI 31% to 36%), LR+ of 1.50 (95% CI 1.44 to 1.56), and LR- of 0.00 (95% CI 0.00 to 0.95).

CONCLUSION: Plasma GFAP and UCH-L1 in combination, measured ≤24 hours postinjury, demonstrated high sensitivity for clinically significant acute traumatic intracranial lesions. Further research is needed to determine whether deploying these biomarkers in the proposed implementation cohort decreases avoidable brain CT scans.

来源:Ann Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Roberts NB, Xie T, Falk H, et al. Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase L1 for Acute Traumatic Intracranial Lesions: The PIONEER Diagnostic Accuracy Study. Ann Emerg Med. 2025. PMID: 41071136. doi:10.1016/j.annemergmed.2025.09.012

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。